NewAmsterdam Pharma Company NV (NASDAQ:NAMS) shares, rose in value on Friday, November 01, with the stock price up by 4.70% to the previous day’s close as strong demand from buyers drove the stock to $17.82.
Actively observing the price movement in the last trading, the stock closed the session at $17.02, falling within a range of $16.51 and $17.87. Referring to stock’s 52-week performance, its high was $26.35, and the low was $8.64. On the whole, NAMS has fluctuated by 1.42% over the past month.
With the market capitalization of NewAmsterdam Pharma Company NV currently standing at about $1.60 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2024-Aug-07.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 1.87M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that NAMS’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of NAMS currently trading nearly -3.82% and 3.63% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 47.50, while the 7-day volatility ratio is showing 6.20% which for the 30-day chart, stands at 4.79%. Furthermore, NewAmsterdam Pharma Company NV (NAMS)’s beta value is -0.00, and its average true range (ATR) is 0.90.
A comparison of NewAmsterdam Pharma Company NV (NAMS) with its peers suggests the former has fared considerably weaker in the market. NAMS showed an intraday change of 4.70% in last session, and over the past year, it grew by 92.44%%.
Data on historical trading for NewAmsterdam Pharma Company NV (NASDAQ:NAMS) indicates that the trading volumes over the past 10 days have averaged 0.21 and over the past 3 months, they’ve averaged 295.70K. According to company’s latest data on outstanding shares, there are 82.47 million shares outstanding.
Nearly 51.64% of NewAmsterdam Pharma Company NV’s shares belong to company insiders and institutional investors own 37.71% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.55 million shares as on 2024-10-15, resulting in a short ratio of 2.12. According to the data, the short interest in NewAmsterdam Pharma Company NV (NAMS) stood at 103.00 of shares outstanding as of 2024-10-15; the number of short shares registered in 2024-09-13 reached 0.42 million. The stock has risen by 59.53% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NAMS stock heading into the next quarter.
